Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 1.00 |
| ▸ | BTK | Q06187 | 5/20 | 0.58 |
| ▸ | JAK1 | P23458 | 4/20 | 0.58 |
| ▸ | TYK2 | P29597 | 4/20 | 0.58 |
| ▸ | JAK3 | P52333 | 4/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143518 | 1.00 | JAK2 (1.00) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL142426 | 0.95 | JAK2 (0.90) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL178602 | 0.93 | JAK2 (0.87) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL178599 | 0.88 | JAK2 (0.78) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL143718 | 0.86 | JAK2 (0.75) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL142323 | 0.85 | JAK2 (0.75) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL140338 | 0.81 | JAK2 (0.69) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL145826 | 0.81 | JAK2 (0.68) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL141921 | 0.80 | JAK2 (0.67) | JAK2BTKJAK1TYK2JAK3 | |
| SCHEMBL178682 | 0.80 | JAK2 (0.80) | JAK2BTKJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885BTK 79/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.